EXEL Exelixis Inc
- Stocks
- Healthcare
- NASDAQ: EXEL
Price (delayed)
$40.87
Market cap
$10.96B
P/E Ratio
16.61
Dividend/share
N/A
EPS
$2.46
Enterprise value
$10.76B
Relative Growth:
Rel. Growth:
97
Relative Strength:
Rel. Strength:
63
Relative Valuation:
Rel. Valuation:
76
Relative Profitability:
Rel. Profitability:
99
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work
Highlights
The company's EPS has surged by 56% YoY and by 14% QoQ
The P/E is 54% below the 5-year quarterly average of 35.6 and 9% below the last 4 quarters average of 18.1
EXEL's quick ratio is up by 8% since the previous quarter but it is down by 6% year-on-year
The company's equity rose by 6% QoQ but it fell by 5% YoY
Key stats
What are the main financial stats of EXEL
Market
Valuations
Earnings
Shares outstanding
268.11M
Market cap
$10.96B
Enterprise value
$10.76B
Price to earnings (P/E)
16.61
Price to book (P/B)
5.09
Price to sales (P/S)
4.79
PEG
0.3
EV/EBIT
12.32
EV/EBITDA
11.6
EV/Sales
4.7
Revenue
$2.29B
Gross profit
$2.21B
Operating income
$800.18M
Net income
$677.9M
EBIT
$873.29M
EBITDA
$927.6M
Free cash flow
$779.77M
Per share
Balance sheet
Liquidity
EPS
$2.46
EPS diluted
$2.37
Free cash flow per share
$2.91
Book value per share
$8.03
Revenue per share
$8.52
TBVPS
$10.28
Total assets
$2.82B
Total liabilities
$662.85M
Debt
$176.46M
Equity
$2.16B
Working capital
$1.03B
Debt to equity
0.08
Current ratio
3.75
Quick ratio
3.47
Net debt/EBITDA
-0.22
Margins
Efficiency
Dividend
EBITDA margin
40.5%
Gross margin
96.6%
Net margin
29.6%
Operating margin
35%
Return on assets
24%
Return on equity
31.6%
Return on invested capital
37.5%
Return on capital employed
35.6%
Return on sales
38.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXEL stock price
How has the Exelixis stock price performed over time
Intraday
1.24%
1 week
4.96%
1 month
2.15%
1 year
15.09%
YTD
22.73%
QTD
-1.04%
Financial performance
How have Exelixis's revenue and profit performed over time
Revenue
$2.29B
Gross profit
$2.21B
Operating income
$800.18M
Net income
$677.9M
Gross margin
96.6%
Net margin
29.6%
Exelixis's operating income has surged by 53% YoY and by 14% QoQ
The company's net income rose by 45% YoY and by 13% QoQ
EXEL's operating margin is up by 39% year-on-year and by 11% since the previous quarter
The net margin has increased by 32% YoY and by 10% from the previous quarter
Price vs fundamentals
How does EXEL's price correlate with its fundamentals
Growth
What is Exelixis's growth rate over time
Valuation
What is Exelixis stock price valuation
P/E
16.61
P/B
5.09
P/S
4.79
EV/EBIT
12.32
EV/EBITDA
11.6
EV/Sales
4.7
The company's EPS has surged by 56% YoY and by 14% QoQ
The P/E is 54% below the 5-year quarterly average of 35.6 and 9% below the last 4 quarters average of 18.1
EXEL's P/B is 52% above its 5-year quarterly average of 3.3
The company's equity rose by 6% QoQ but it fell by 5% YoY
The revenue has grown by 10% YoY and by 2.6% from the previous quarter
EXEL's price to sales (P/S) is 8% higher than its 5-year quarterly average of 4.4
Efficiency
How efficient is Exelixis business performance
The ROIC has grown by 49% YoY and by 16% from the previous quarter
The company's return on equity rose by 48% YoY and by 14% QoQ
The ROA has grown by 47% YoY and by 14% from the previous quarter
The company's return on sales rose by 33% YoY and by 10% QoQ
Dividends
What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXEL.
Financial health
How did Exelixis financials performed over time
EXEL's quick ratio is up by 8% since the previous quarter but it is down by 6% year-on-year
EXEL's current ratio is up by 7% since the previous quarter but it is down by 4.6% year-on-year
The debt is 92% less than the equity
The company's debt to equity fell by 11% QoQ and by 11% YoY
The debt has decreased by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.